IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model

References

• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33–63.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology and the effect of the immune system on bone. Nat Rev Rheumatol. 2009;5(12):667–76.
   PubMedGoogle Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
   PubMed Web of Science ®Google Scholar
• Mclnnes JB, Schett G. Cytokines in the pathogeneses of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42.
   PubMedGoogle Scholar
• Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63(2):149–55.
   PubMedGoogle Scholar
• Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthr Rheum. 2003;48(4):927–34.
   PubMed Web of Science ®Google Scholar
• Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci. 2005;1051:799–810.
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Mclnnes IB. Th17 cells and IL-17 A-Focus on immunopathology and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158–70.
   PubMedGoogle Scholar
• Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA. 1992;89(16):7375–9.
   PubMedGoogle Scholar
• Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 1992;77(4):510–4.
   PubMedGoogle Scholar
• Campbell IK, O’Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001;107(12):1519–27.
   PubMedGoogle Scholar
• Ji H, Pettit A, Ohmura K, Oriz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med. 2002;196(1):77–85.
   PubMedGoogle Scholar
• Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007;204(1):41–7.
   PubMed Web of Science ®Google Scholar
• Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA. 2003;100(10):5986–90.
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sodo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–7.
   PubMed Web of Science ®Google Scholar
• Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, et al. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol. 2008;181(1):329–37.
   PubMedGoogle Scholar
• Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009;21(3):224–30.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43–50.
   PubMed Web of Science ®Google Scholar
• Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthr Rheum. 1998;41(12):2117–21.
   PubMedGoogle Scholar
• Kagari T, Doi H, Shimozato T. The importance of IL-1β and TNF-α, and the non-involvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002;169(9):1459–66.
   PubMedGoogle Scholar
• Sato-Hayashizaki A, Ohtsuji M, Lin Q, Hou R, Ohtsuji N, Nishikawa K, et al. Presumptive role of 129 strain-derived Sle16 locus in rheumatoid arthritis in a new mouse model with Fcγ receptor Type IIb-deficient C57BL/6 genetic background. Arthr Rheum.2011;63(10):2930–8.
   PubMedGoogle Scholar
• Okazaki H, Lin Q, Nishikawa K, Ohtsuji N, Tsurui H, Ohtsuji M, et al. TNFα but not IL-17 is critical in the pathogenesis of rheumatoid arthritis spontaneously occurring in a unique FcγRIIB-deficient mouse model. Modern Rheum. DOI: 10.3109/14397595.2014.886351
   Google Scholar
• Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature. 1996;379(6563):346–9.
   PubMedGoogle Scholar
• Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad. Sci USA. 1993;90(24):11924–8.
   PubMedGoogle Scholar
• Abe Y, Ohtsuji M, Ohtsuji N, Lin Q, Tsurui H, Nakae S, et al. Ankylosing enthesitis associated with up-regulated IFN-γ and IL-17 production in (BXSB × NZB) F1 male mice: a new mouse model. Mod Rheumatol. 2009;19(3):316–22.
   PubMedGoogle Scholar
• Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Santiago-Raber M-L, Amano H, Amano E, Fossati-Jimack L, Moll T, et al. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J Immunol. 2006;176(5):3240–7.
   PubMedGoogle Scholar
• Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J. 2008;275(18):4448–55.
   PubMedGoogle Scholar
• Yu RY-L, Wang X, Pixley FJ, Yu J, Dent AL, Broxmeyer DH, et al. BCL-6 negatively regulated macrophage proliferation by suppressing autocrine IL-6 production. Blood. 2005;105(4):1777–84.
   PubMedGoogle Scholar
• Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007:13(2);139–45.
   PubMedGoogle Scholar
• Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity. 2000;13(2):277–85.
   PubMedGoogle Scholar
• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243–54.
   PubMedGoogle Scholar
• Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227–36.
   PubMedGoogle Scholar
• Dayer J-M, Choy E. Therapeutic targests in rheumatoid arthritis: the interleukn-6 receptor. Rheumatology. 2010;49(1):15–24.
   PubMedGoogle Scholar
• Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002;196(7):979–90.
   PubMedGoogle Scholar
• Palmqvist P, Persson E, Conaway HH, U.H. Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB in mouse calvariare. J Immunol. 2002;169(6):3353–62.
   PubMedGoogle Scholar
• Hashizume M, Hayakawa N. Mihara M. IL-6 trans-signalling directly induces RANKL on fobroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology. 2008;47(11):1635–40.
   PubMedGoogle Scholar
• Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewing MK, Schwartz SM, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. 1998;161(11):6113–21.
   PubMedGoogle Scholar
• Zannettio ACW, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, et al. Osteoprotegerin (0PG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005;204(2):714–23.
   PubMedGoogle Scholar
• Catrina AI, af Klint E, Ernestam S, Catrina S-B, Makrygiannakis D, Botusan IR, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthr Rheum. 2006;54(1):76–81.
   PubMedGoogle Scholar
• Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Annn N Y Acad Sci. 2006;1068:225–33.
   PubMedGoogle Scholar
• Feldmann M, Brennan FM, Maini RN. Rheumatoid Arthritis. Cell. 1996;85(3):307–10.
   PubMedGoogle Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
   PubMed Web of Science ®Google Scholar
• Ducreux J, Durez P, Galant C, Toukap AN, Van de Eynde B, Houssiau FA, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthr Rheum. 2014; 66(1):15–23.
   PubMedGoogle Scholar